Dopamine receptor types D1 and D2 can oppose or enhance each other's actions for electrical, biochemical, and psychomotor effects. We report a D1-D2 interaction in homogenized tissue as revealed by ligand binding. D2 agonists The blocking effect by SCH 23390 was similar to that produced by a nonhydrolyzable guanine nucleotide analogue, and SCH 23390 reduced the number of agonist-labeled D2 receptors in the high-affinity state. Thus, the Dj-D2 link may be mediated by guanine nucleotide-binding protein components. The link may underlie D1-D2 interactions influencing behavior, since the link was missing in over half the postmortem striata from patients with schizophrenia and Huntington disease (both diseases that show some hyperdopamine signs) but was present in human control, Alzheimer, and Parkinson striata.
Many psychomotor signs and symptoms are influenced by drugs that act selectively on brain dopamine receptors. These include rigidity in Parkinson disease, dyskinesias in Huntington disease, hallucinations in schizophrenia, and oral dyskinesia in the elderly. Since dopamine can excite or inhibit neurons (1) , and stimulate or inhibit adenylate cyclase (2) , it has been proposed (3) that there are two types of dopamine receptors, D1 and D2 (see ref. 4 for review). These two receptors enhance each other's action for many psychomotor mechanisms, including body motion (5) and neuron firing (6) . The two receptors can also oppose each other, as in controlling mouth motion (7) or cAMP efflux from tissue slices (8) . Despite numerous such examples (9) , there is little information on possible molecular mechanisms explaining these D1-D2 interactions. We here report a link between D1 and D2 receptors in homogenized tissue, revealed by the method of ligand binding, and that this link mechanism is similar to, or part of, the guanine nucleotide-binding protein (G-protein) system (10) that mediates some of the actions of dopamine receptors (2, 4) . The link may underlie D1-D2 interactions influencing behavior, since the link was missing in more than half the postmortem striata from patients with schizophrenia or Huntington disease but was present in postmortem striata from individuals without neurodegenerative disease or with Alzheimer or Parkinson disease.
METHODS Binding of [3H]
Raclopride to D2 Receptors. The centrifugation method (11) was used for [3H]raclopride binding. Frozen canine brain striata were from Pel-Freez Biologicals. The tissues were washed twice in buffer (50 mM Tris-HCl, pH 7.4/1 mM EDTA/120 mM NaCl/5 mM KCl/1.5 mM CaCl2/4 mM MgCl2). Porcine anterior pituitary tissues (Bocknek Organic Materials, Rexdale, ON) were prepared as described (12) . The final concentrations (in 1 ml) were 1 mg of original tissue per ml (with 0.1% ascorbic acid for canine tissues only) and from 20 pM to 15 nM [3H]raclopride (64-87 Ci/mmol; DuPont; 1 Ci = 37 GBq) with or without 10 AM (S)-sulpiride (Ravizza, Milan) to define nonspecific binding. The filtration method was used in some experiments; the tube contents were filtered and rinsed with 7 ml of buffer through a 7034 filter (Skatron, Sterling, VA), using a Skatron cell harvester. The saturation data were analyzed by both the LIGAND program (references in ref. 4 ) and simple regression analysis. The LIGAND-assisted analysis indicated that a two-site fit was not significantly better than a one-site fit.
Photolabeling of Receptors. D1 receptors were photolabeled by the method of Niznik et al. (13) and D2 receptors by that of Jarvie et al. (14) . Canine striatal membranes were Teflon/ glass-homogenized in 25 mM Tris.HC1/250 mM sucrose buffer (pH 7.4, 4°C) with protease inhibitors (EDTA, 20 mM; benzamidine, 15 ,ug/ml; leupeptin, 5 ,g/ml; soybean trypsin inhibitor, 5 ,ug/ml; phenylmethanesulfonyl fluoride, 1 mM) and centrifuged for 10 min at 400 x g. The supernatant was subsequently recentrifuged at 48,000 x g for 20 min. Membrane pellets were resuspended in Tris HCl buffer containing 120 mM NaCl and protease inhibitors ( 
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RESULTS
To search for D1-D2 interactions in vitro, [3H] raclopride (15) is ideal, since it is highly selective for D2 receptors (4) but is loosely bound to D2 (Kd 1900 pM) and thus readily sensitive to the presence of dopamine (16) .
The addition of dopamine lowered the binding (16) of [3H]raclopride to D2 receptors, in agreement with previous observations (12, 17, 18) . The novel aspect, however, was that this apparent decrease in D2 density was inhibited by preincubation with a Dl-selective drug (SCH 23390) that by itself had no effect on the properties of [3H]raclopride binding (Fig. 1A) (19, 20) , revealed the dopamine-induced decrease in [3Hlraclopride binding but did not show the inhibition of this effect by SCH 23390 (Fig. 1D ) as seen in striatum (Fig.  IA) . However, the dopamine-induced depression of [3H]-raclopride binding could be inhibited in both the striatum and anterior pituitary homogenates by preincubation with 5'-guanylyl imidodiphosphate ( Fig. 1 B and D) , indicating that the G-protein system was operative, an effect seen previously (12) .
To determine the drug selectivity of the dopamine-induced depression of [3H]raclopride to the D2 sites, the rank order of agonist potency in depressing [3H]raclopride binding was examined and found to be dopamine > norepinephrine > epinephrine > serotonin ( (4) , concentrations of 50 nM or higher were considered to be an excess for D1 blockade. The control tissue and the SCH 23390-pretreated tissues came from the same original homogenate, and the two batches of homogenate were treated side-by-side in an identical fashion, except that one beaker contained 200 nM SCH 23390 during the preincubation hour. The final concentration of tissue during preincubation was 4-fold higher than that in the final incubation. Since SCH 23390 by itself had no effect on the binding of (Fig. 3) .
Although the D1-D2 effect ( Fig. 1) (Fig. 4B ).
Since an important role for the D1-D2 link may be in diseases such as schizophrenia and Huntington disease (11) which include hyperdopamine signs and symptoms, we sought evidence for this possibility. We found that the D1-D2 link existed in human control striata (11 tissue samples), Alzheimer disease striata (7 samples), and Parkinson disease striata (6 samples 
DISCUSSION
The data suggest the following interpretation (Fig. 7) 
